SUNNYVALE, Calif., Oct. 2, 2019 /PRNewswire/ -- Cepheid today announced that it has received clearance from the U.S. Food and Drug Administration for Xpert BCR-ABL Ultra for monitoring disease burden ...
AcroMetrix BCR-ABL External Molecular Panel: An Accurate Testing Method for Chronic Myeloid Leukemia
To support the validation and verification of new assays and to challenge the existing assays in oncology testing, Thermo Fisher Scientific launches Thermo Scientific Acrometrix BCR-ABL Panel. The ...
Expression of CD74 by AML blasts and cell lines, and enhanced in vitro cytotoxicity of anti-CD74 antibody after interferon-gamma (IFN-γ) treatment. Background: Current NCCN guidelines recommend ...
FRANKLIN LAKES, N.J. and PORTLAND, Ore., June 2, 2011 /PRNewswire/ -- Medco Health Solutions, Inc. (NYSE: MHS) and MolecularMD Corp. today announce the launch of a personalized medicine program for ...
FREMONT, Calif., Oct. 17, 2019 /PRNewswire/ -- Thermo Fisher Scientific, the world leader in serving science, today announced the availability of the Thermo Scientific Acrometrix BCR-ABL Panel, its ...
Genetic testing for chronic myeloid leukemia (CML) can tell doctors if someone has leukemia, what type they may have, and whether treatment is working. The tests look for atypical changes in certain ...
PORTLAND, Ore. & CAMBRIDGE, Mass.--(BUSINESS WIRE)-- MolecularMD Corp. and ARIAD Pharmaceuticals, Inc. (NAS: ARIA) today announced that MolecularMD has voluntarily withdrawn its Premarketing Approval ...
Tuberculosis infection in chronic myeloid leukemia (CML) patients treated with imatinib. Background: The BCR-ABL fusion gene results from the translocation t(9;22). It is the hallmark of chronic ...
ARIAD Pharmaceuticals, Inc.Kendra Adams, 617-503-7028orLiza Heapes, 617-621-2315orKatherine Clock, 503-459-4974 and (NASDAQ: ARIA) today announced that MolecularMD has voluntarily withdrawn its ...
Chronic myeloid leukemia (CML) is a myeloproliferative disorder characterized by the t(9;22) translocation coding for the chimeric protein p210 BCR-ABL. The tumor suppressor phosphatase and tensin ...
Asuragen will develop international scale calibrators and software reporting tools. Asuragen inked an exclusive agreement with Novartis to develop international scale (IS) calibrators and laboratory ...
The oncology landscape is rapidly evolving with new biomarker discoveries and potential targeted treatment options. Consequently, the medical community must work together to develop timely and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results